Atrial fibrillation (AF) is the most frequent arrhythmia in patients >55 years old and is related to ischemic stroke due to thrombi formation in the left atrium, particularly in the atrial appendage. To avoid this complication, anticoagulation is indicated, but patients >75 years are at high risk of bleeding, making percutaneous closure of the atrial…
Alcohol Septal Ablation and Pacemaker Implantation: Results After 5 Years
Alcohol septal ablation is used to treat patients with obstructive hypertrophic cardiomyopathy. A significant complication in this intervention is atrioventricular block requiring pacemaker implantation in 7% to 20% of cases. Current evidence is limited for clinical results at follow-up for these patients. The aim of this study was to evaluate the results for patients with…
Prognosis After Pacemaker Implantation in Alcohol Septal Ablation
One of the main complications of alcohol septal ablation (ASA) is the alteration in the conduction system, which could lead to permanent pacemaker (PPM) implantation. This is mainly due to the relationship between septal perfusion and the conduction system (especially the right bundle branch). The incidence reported in the literature is 7% to 20% of…
TCT 2022 | AMULET IDE: Events at 3 Years Using the AMULET Appendage Closure Device
The aim of this study was to assess the 3-year efficacy for the endpoints of the AMULET Occluder (Abbott) left atrial appendage closure device compared with the Watchman 2.5 device. The evaluated endpoints were analyzed according to a “per protocol” population, assessing a composite of stroke, systemic embolism, or cardiovascular death. The secondary endpoints were…
Left Atrial Appendage Closure Is Safe with the New Devices
Left atrial appendage closure (LAAC) in non-valvular atrial fibrillation with high risk of bleeding has shown promising results with first generation devices (with the Watchman) in the different studies. At present, we have a more modern device, the Watchman FLX, but we do not have much information about it. To gather more data, researchers looked…
SOLACI-SOCIME 2022 | Cierre de CIA tipo seno venoso superior: ¿Un nuevo invitado en la mesa? by Dr. Juan Pablo Sandoval
Read the most outstanding articles from the first day of the SOLACI-SOCIME 2022 Congress. In this case, consult the presentation by Dr. Juan Pablo Sandoval, entitled “Cierre de CIA tipo seno venoso superior: ¿Un nuevo invitado en la mesa?”
Peridevice Leak in Left Atrial Appendage Closure: more than one value to take into account
According to several registries, incomplete left atrial appendage (LAA) closure has been observed in up to 30% of cases after device implantation. The main cause of this complication is a mismatch between closure device and LAA ostium. The latter is elliptical in shape and varies in length, while the Watchman LAA closure device is round…
Tricuspid Regurgitation: Edge-to-Edge Treatment with PASCAL
About 4% of the population suffers from tricuspid regurgitation (TR). This disease is associated with hard-to-manage heart failure (HF)—often requiring hospitalization—and with mortality. Surgery in this valve is not simple and has high morbidity and mortality rates due to its comorbidities. Currently, a percutaneous strategy for its resolution is under development, but we still do…
TRAPEUR Registry: Thrombus Trapping with Left Atrial Appendage Closure Device
Left atrial appendage closure (LAAC) devices are a good alternative for the prevention of systemic thromboembolism in patients with non-valvular atrial fibrillation (AF) and high risk of bleeding or those with anticoagulation contraindication. According to PRAGUE-17 outcomes, at 4 years, LAAC resulted non-inferior to direct anticoagulation in the prevention of cardiovascular, neurological, and bleeding events. …
Hypertrophic Cardiomyopathy: Analyzing a Historical Series
75% of patients with hypertrophic Cardiomyopathy present symptoms. An important group responds very well to pharmacological treatment with betablockers and calcium antagonists, and those who do not respond, or do not tolerate these drugs, receive, at present, surgery as elective treatment. There is also alcohol septal ablation as an alternative strategy, which different studies have…
Should We Use Left Atrial Appendage Occlusion More Frequently? What Real-Life Data Are Available?
Left atrial appendage occlusion (LAAO) is an alternative to prevent atrial fibrillation stroke mainly used in patients at high risk for bleeding. One of the most widely used devices in randomized trials is the Watchman, which yielded promising results. However, its real-life performance had yet to be analyzed. Researchers conducted an analysis of the National…